FDA clears Great Smokies' intestinal permeability test:
This article was originally published in Clinica
Executive Summary
Great Smokies Diagnostic Laboratory (GSDL) has received US FDA 510(k) clearance for its non-invasive test for measuring intestinal permeability, a measurement used to help diagnose gastrointestinal malabsorption syndromes, such as coeliac disease, Crohn's disease and irritable bowel syndrome. The intestinal permeability test kit is more sensitive than the existing d-xylose test, said the Asheville, North Carolina-based company, which also noted that it was the first commercial laboratory to offer intestinal permeability testing.
You may also be interested in...
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.